ArticleAddiction (Abingdon, England)2020
Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
Article in Addiction (Abingdon, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A systematic review of virtual reality therapies for substance use disorders: Impact on secondary treatment outcomes.The American journal on addictions · 2023Pooled it
- Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.Contemporary clinical trials · 2023Trial
- Trial
- Excess mortality following discharge from substance use disorder treatment in Chile.Addiction (Abingdon, England) · 2026Article
- Leveraging a digital health intervention to improve recovery outcomes among people with substance misuse experiencing housing insecurity.Drug and alcohol dependence · 2026Article
- Enhancing Naloxone Distribution for Opioid Users in the USA: A Cost-Utility Analysis of Academic Detailing to Clinicians.Applied health economics and health policy · 2025Article
- Bed-based care as a response to the overdose crisis: an approach to informing and evaluating proposed expansion.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Correlates of residential detoxification completers and non-completers in Alberta.Substance abuse treatment, prevention, and policy · 2025Article
- Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study.Drug and alcohol dependence · 2025Article
- Attitudes and Subjective Norms Regarding Medication for Opioid Use Disorder Among Individuals in Treatment for Opioid Use Disorder in the Greater St. Louis Area.Journal of drug issues · 2025Article
- Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal.Cureus · 2025Article
- Implementing and documenting cultural adaption of evidence-based practice strategies to reduce opioid overdose deaths: examples and lessons from the HEALing communities study.Discover public health · 2025Article
- Drug Overdose Death Following Substance Use Disorder Treatment Termination in New York City: A Retrospective Longitudinal Cohort Study.Journal of urban health : bulletin of the New York Academy of Medicine · 2024Article
- An Approach to Enhancing Medication Treatment for Opioid Use Disorder in the HEALing Communities Study.Psychiatric services (Washington, D.C.) · 2024Article
- Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan.Psychotherapy and psychosomatics · 2024Article
- Differential risks of syringe service program participants in Central Ohio: a latent class analysis.Harm reduction journal · 2023Article
- Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder.The American journal of psychiatry · 2023Article
- A mobile addiction service for community-based overdose prevention.Frontiers in public health · 2023Article
- Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.Addiction (Abingdon, England) · 2022Article
- Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.Addiction science & clinical practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimMedically managed opioid withdrawal (detox) can increase the risk of subsequent opioid overdose. We assessed the association between mortality following detox and receipt of medications for opioid use disorder (MOUD) and residential treatment after detox.
designCohort study generated from individually linked public health data sets.
settingMassachusetts, USA.
participantsA total of 30 681 opioid detox patients with 61 819 detox episodes between 2012 and 2014. MEASUREMENTS: Treatment categories included no post-detox treatment, MOUD, residential treatment or both MOUD and residential treatment identified at monthly intervals. We classified treatment exposures in two ways: (a) 'on-treatment' included any month where a treatment was received and (b) 'with-discontinuation' individuals were considered exposed through the month following treatment discontinuation. We conducted multivariable Cox proportional hazards analyses and extended Kaplan-Meier estimator cumulative incidence for all-cause and opioid-related mortality for the treatment categories as monthly time-varying exposure variables.
findingsTwelve months after detox, 41% received MOUD for a median of 3 months, 35% received residential treatment for a median of 2 months and 13% received both for a median of 5 months. In on-treatment analyses for all-cause mortality compared with no treatment, adjusted hazard ratios (AHR) were 0.34 [95% confidence interval (CI) = 0.27-0.43] for MOUD, 0.63 (95% CI = 0.47-0.84) for residential treatment and 0.11 (95% CI = 0.03-0.43) for both. In with-discontinuation analyses for all-cause mortality, compared with no treatment, AHRs were 0.52 (95% CI = 0.42-0.63) for MOUD, 0.76 (95% CI = 0.59-0.96) for residential treatment and 0.21 (95% CI = 0.08-0.55) for both. Results were similar for opioid-related overdose mortality.
conclusionsAmong people who have undergone medically managed opioid withdrawal, receipt of medications for opioid use disorder, residential treatment or the combination of medications for opioid use disorder and residential treatment were associated with substantially reduced mortality compared with no treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.